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Abstract
Autoimmune Inner Ear Disease (AIED) is poorly characterized clinically, with no definitive laboratory test. All patients
suspected of having AIED are given glucocorticoids during periods of acute hearing loss, however, only half initially
respond, and still fewer respond over time. We hypothesized that AIED is a systemic autoimmune disease characterized by
dysfunctional peripheral blood mononuclear cells (PBMC) responses to a unique cochlear antigen(s). To test this hypothesis,
we examined end-stage AIED patients undergoing cochlear implant surgery and compared autologous perilymph
stimulated PBMC from AIED patients to controls. We determined that autologous perilymph from AIED patients was unable
to induce expression of a long membrane-bound Interleukin-1 Receptor Type II (mIL1R2) transcript in PBMC as compared
with controls, despite similar expression of the short soluble IL1R2 (sIL1R2) transcript (p,0.05). IL1R2 is a molecular decoy
that traps interleukin-1b (IL-1b) and does not initiate subsequent signaling events, thereby suppressing an inflammatory
response. IL1R2 transcript length is regulated by alternate splicing, and the major inhibitory function is attributed to the full-
length mIL1R2. In addition, IL1R2 expression is induced by dexamethasone. Separately, we prospectively examined
patients with newer onset glucocorticoid-responsive AIED. Immediately prior to clinical treatment for acute deterioration of
hearing thresholds, their PBMC demonstrated a robust induction of mIL1R2 in PBMC in response to dexamethasone in vitro
that correlated with a clinical response to prednisone in vivo (p,0.0001) as measured by hearing restoration. In contrast,
clinically steroid unresponsive patients demonstrated high basal levels of mIL1R2 in their PBMC and only minimally
augmented expression in response to dexamethasone. Thus, induced expression of mIL1R2 appears to be a protective
mechanism in hearing homeostasis and warrants further investigation in a large prospective clinical trial to determine if
IL1R2 can be used as a specific biomarker for AIED.
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Introduction
Sensorineural hearing loss (SNHL) is a common otologic
problem that typically is not amenable to medical intervention.
Potentially reversible SNHL can be divided into two sub-groups:
(1) Autoimmune Inner Ear Disease (AIED) and (2) sudden SNHL
(SSNHL). Timely administration of glucocorticoids in these two
conditions may result in hearing preservation. While SSNHL is
usually an isolated, unilateral and single event, patients with AIED
usually experience multiple episodes of rapid hearing loss in both
ears. This disorder can be an isolated process affecting the ear
only, or it may be part of a systemic autoimmune disorder in
approximately 30% of those afflicted [1]. Further characterization
of AIED has been hampered by limited access to the inner ear,
and by the absence of a reliable biomarker that distinguishes AIED
from patients with other forms of SNHL [2]. Thus, the incidence
and prevalence of AIED is unknown, however an initial response
to glucocorticoids may assist to define this clinical disorder
[1,3,4,5]. In patients with AIED, hearing preservation with
glucocorticoids is often only maintained short term [3,6]. Of the
60 [3] to 70% [6] of patients who are initially steroid responsive,
only 14% remain so after 34 months [6]. It is unknown whether
these patients who initially respond, and then become refractory to
steroid therapy, have undergone a change in immune response
that precludes continued response to corticosteroids. Moreover, on
a molecular level, it is unknown how steroids induce a clinical
response.
Medical therapy for AIED patients refractory to corticosteroids
is limited. Methotrexate has been shown to be beneficial in several
small series; however, in a large prospective trial, methotrexate
was comparable to placebo in maintaining hearing in AIED
patients [5]. In animals, suppression of TNFa by Etanercept was
helpful in treating AIED, however, a recent human clinical trial
failed to confirm this [7]. When medical therapy fails to restore
hearing, and hearing aids are no longer beneficial, cochlear
implantation is often used to restore hearing in patients with AIED
who develop bilateral, severe to profound SNHL. Identification of
a more effective medical therapy for AIED is contingent on
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5293developing a better understanding of the mechanism(s) that cause
this disorder.
A much more common entity treated with corticosteroid
therapy is sudden sensorineural hearing loss (SSNHL). A fraction
of patients with SSNHL are considered to have AIED [8], as the
majority of these patients are thought to have either viral or
vascular pathophysiologic causes of their disease. Nonetheless,
therapy for all patients with a sudden decline in hearing is similar
and usually treatment entails the prompt use of corticosteroids.
Evidence of an autoimmune mechanisms being important in
SSNHL has been reported, and includes an increased prevalence
of antibodies specific for a HSP70 (a heat shock protein),
commonly found in the blood of a cohort of SSNHL patients
[9], and an increased frequency of the HLA-DRB1*04 allele in
SSNHL, which is associated with a poor response to glucocorti-
coids [10]. HLA-DRB1*04 has also been associated with other
autoimmune disorders such as autoimmune thyroiditis and
rheumatoid arthritis [11,12].
Many autoantibodies to cochlear and other self-antigens in human
serumhavebeenshowntobeenrichedinAIEDpatients.Presumptive
markers for AIED that has been identified include autoantibodies to:
ANA (18–43%), HSP70 (22–89%) and others (recently reviewed
[13]). However, no single antibody is present in all patients with this
disease [2]. An increased prevalence of several autoantibodies have
correlated with glucocorticoid-responsive AIED, including antibodies
to both HSP70 [14] and CTCL2, recently suggested to be a
biomarker for this disease [15]. HSP 70 garnered a great deal of
attention because of its high specificity for AIED [14]; however its
pathogenic role is controversial [16], since mice immunized with
bovine HSP 70 failed to experience hearing loss [17].
Animal models of AIED have demonstrated that the inner ear is
accessible from the peripheral circulation and no strict anatomic
barrier exists within the cochlea. Immunocytes have been shown
to traffic into the inner ear from the peripheral circulation [2,18],
and radiolabeled lymphocytes have been shown to enter the scala
tympani of the cochlea [2,18]. Furthermore, T cells from the
systemic circulation have been shown to proliferate in the
endolymphatic sac, and perilymph proteins of the cochlea can
activate immunocytes in the endolymphatic sac [19]. These
passive transfer experiments suggest that there is no anatomic
barrier to trafficking lymphocytes from the systemic circulation
into the inner ear.
Recent animal studies suggest that macrophages (MF), which are
part of the innate immune response, can augment adaptive T-cell
responses made in AIED [20]. In these experiments, re-exposure to
KLH antigen in the presence of systemic lipopolysaccharide (LPS)
caused upregulation of Interleukin-1b (IL-1b) expression in the
cochlea, leukocyte entry into the cochlea, and subsequent hearing
loss. As anticipated, LPS induced Toll Like Receptor 4 (TLR4)
signaling and augmented IL-1b expression and was associated with
hearing loss. These experiments suggest that the innate immune
system may participate in the development of AIED [20]. In
addition, the production of IL-1b by MF, likely causes T-cell
polarization to Th1-like response that might perpetuate AIED. A
critical role of pro-inflammatory CD4+, Th1-like T-cells has been
shown in the cochlin peptide-murine model [21]. Interferon-gamma
(IFNc)-producing, Th1-like T cells have been identified in the
peripheral blood of AIED patients [22]. Modulation of interleukin-
1b levels has resulted in IFN-c expression by T-cells in other
autoimmune disorders. In murine autoimmune encephalomyelitis,
blockade of the IL-1 receptor antagonist (IL-1RA) permits soluble
IL-1b to bind the IL-1 receptor type 1 (IL-1R1), augmenting the
development of clinical encephalomyelitis and T-cells expression of
IFN-c [23]. Thus, the absence of IL-RA expression, or other
molecules that oppose the IL-1b inflammatory cascade, during an
immune response, can promote the development of autoimmune
disease, including AIED.
Results
We hypothesized that patients with AIED have a systemic
immunologic disease manifested in the inner ear initiated by a
unique cochlear antigen. Given that PBMC are capable of
trafficking to the inner ear during inflammation [2], we anticipated
that immunocytes that had previously encountered a cochlear
antigen would respond differently to cochlear proteins compared
with those that had not been previously exposed. For this reason,
we compared the effect of adding autologous perilymph to
peripheral blood mononuclear cells (PBMC) in patients with AIED
who underwent cochlear implantation (end stage disease) com-
pared to PBMC from patients undergoing implantation for
longstanding, non-immunologic, stable, SNHL (hereafter called
controls) using RNA expression microarray analysis. Patient data
can be seen in table 1. Results for each patient were compared to
unstimulated autologous PBMC (negative control) and pneumo-
coccal-stimulated autologous PBMC. The rationale for the
pneumococcal stimulation is that the standard care for all patients
undergoing cochlear implantation is prior immunization with
pneumococcal vaccine to prevent meningitis [24]. Thus, all
patients were primed by vaccination with a 23-valent-pneumo-
coccal vaccine (PneumovaxH). The majority of those with AIED
also had systemic autoimmune disease. Interestingly, none of these
subjects had the same autoimmune disorder, reducing the
possibility of a single class II HLA allele as the mediating factor.
Microarray results for AIED and control subjects were analyzed
by comparing unstimulated PBMC, with autologous perilymph
stimulated, and pneumococcal stimulated, PBMC (figure 1A).
Analysis of the microarray data was performed by normalizing
data sets by RMA and an ANOVA analysis was performed on
grouped arrays by condition with a Benjamini and Hochberg
correction, and a threshold of 2.0 fold change (Genesifter,
VixXlabs). Of note, only 10 genes were differentially expressed
in these experiments when the threshold was set at 2 and a
Benjamini & Hochberg correction applied (p,0.05). Of those 10
genes, only one, the interleukin-1 receptor type 2 (IL1R2)
(affymetrix ID 205403, nt 1104–1485 (long membrane bound
form of IL1R2 (mIL1R2)), was differentially expressed when
autologous perilymph was added to PBMC of control subjects, as
compared with AIED subjects (Figure 1A, 1B). Analysis of IL-1RI,
IL-1b, IL-1RA, heat shock proteins (HSP) and TNF-a all failed to
show differential expression (not shown).
IL1R2 Expression
To confirm our microarray results, we used a quantitative real
time polymerase chain reaction (Q-RT-PCR). IL1R2 exists in two
forms: membrane-bound (mIL1R2) and soluble (sIL1R2). The
RNA primers used to detect the membrane bound, long form of
the IL1R2 message were derived from the coding region of the
IL1R2 gene present on the Affymetrix gene array chip (figure 2A).
The shorter soluble form is made by alternative splicing [25], or by
enzymatic cleavage of the membrane bound protein by either a
metalloproteinase, aminopeptidase or elastase [26,27,28], howev-
er, the shed IL1R2 size varies with a metalloproteinase producing
a 45 kD product, and aminopeptidase and elastase producing a
60 kD product [26]. Interestingly, both AIED patients and
controls make transcripts for the shorter form, although at slightly
lower levels in AIED subjects compared with controls (affymetrix
ID 211372, nt 635–1084) (figure 2B). RNA for the longer,
IL1R2 Expression and AIED
PLoS ONE | www.plosone.org 2 April 2009 | Volume 4 | Issue 4 | e5293Figure 1. Differential expression of IL1R2 by microarray in response to autologous cochlear perilymph in patients undergoing
cochlear implantation. 1A Comparison of RNA expression using the Affymetrix U133A 2.0 chip to compare cultured PBMC of controls (CTRL) and
AIED patients for the following conditions: either unstimulated (UNTX), stimulated with 23-valent pneumococcal vaccine (PNEUMO) or autologous
cochlear perilymph (C). Only 10 genes (panel A) were significantly different (p,0.05) when a threshold of 2 and a Benjamini & Hochberg correction
was applied (Genesifter, VixXlabs). Only one of them unique to the cochlear fluid stimulated condition IL1R2 (affy ID 205403), P,0.05. Array data in 1A
can be viewed at www.ncbi.nlm.nih.gov/geo/ using the user ‘‘Vambutas’’ with a password ‘‘daniella’’ to view series ‘‘GSE4277’’ containing 18 arrays
from the six patients with ‘‘1’’ next to their description in table 1. 1B A comparative analysis of IL1R2 expression in these arrays is seen in panel 1B,
with standard deviations shown.
doi:10.1371/journal.pone.0005293.g001
Table 1. Clinical History of AIED and control patients undergoing cochlear implantation.
Patient Status
Autoimmune
History Hearing History PTA & HINT Serology
40 y/o female
1,2 Control (birth anoxia?) None Congenital loss – non
progressive
PTA 100 dB; HINT 60 dB
quiet: 0%
NP*
49 y/o male
1,2 Control None 40+ years loss PTA 100 dB; HINT 50 dB
quiet: 10%
NP*
79 y/o female
1,3 Control (LVA) None 70+ years LVA PTA 110; HINT 55 dB
quiet: 0%;
NP*
1.5 y/o female
3 Control (Cx 26) None Congenital – stable PTA: NR at 102 dB by
ABR; IT-MAIS: 12%
NP*
36 y/o female
1,2 AIED, progressive loss Rheumatoid
Arthritis
29 years, periods
of rapid loss
PTA 120 dB; HINT: 55 dB
quiet: 0%
P0, Rheumatoid factor IgM
(14.2) & IgG (25.3), immune
complex, ANA 1:1280 (HEp-2),
IgM phospholipids (10.9),
immune complex (26.1)
56 y/o male
1,2 AIED, rapid loss Type I IDDM 2 years, rapid loss PTA 120; HINT 70 dB
quiet: 0%
ANA 1:1280 (mouse kidney),
ANA 1:320 (HEp-2),weakly
positive IgM phospholipid Ab
(12.1)
58 y/o female
1,2,3 AIED, rapid loss Hashimoto’s
thyroiditis
4 years, rapid loss PTA 110 dB; HINT at 50
dB quiet: 0%
Borderline for immune
complex (21.4), weakly
positive IgM phospholipids
(11.7), borderline rheumatoid
factor IgG (20.8)
51 y/o female
2,3 AIED, progressive loss None Sudden loss left ear 10
years prior, sudden loss
right ear ,6 months
PTA 80 dB; HINT 65 dB
quiet: 19%
68 kD positive
3 y/o male
3 AIED, b/l rapid SNHL None 6 months, rapid loss PTA 120 dB; IT-MAIS 8% Negative
PTA: Pure tone average of the audiogram at 500, 1000, 2000 and 4000 Hz, (although 4000 Hz is not traditionally included, this information is important to speech
perception for cochlear implantees and therefore PTA represents these four frequencies for these patients). NP: Not Performed: control subjects did not have serology
for AIED performed as there was no clinical indication for such studies, HINT: Hearing in Noise Test; IT-MAIS: Infant-Toddler Meaningful Auditory Integration Scale, LVA:
Large Vestibular Aqueduct; Cx26: connexin 26 gene mutation. Superscript numbers in column 1 refer to inclusion of the patient in data sets for the below figures: 1:
included in analysis for figure 1; 2b & c: included in analysis for figure 2b or 2c. In one patient, all RNA was used for microarray analysis (79 y/o female, control).
doi:10.1371/journal.pone.0005293.t001
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PBMC from AIED patients (no transcript detected at 45 cycles);
however, in perilymph stimulated control PBMC, mIL1R2 RNA
is strongly expressed (figure 2B). The difference was statistically
significant using a Mann Whitney test (p=0.03) (in stat).Notably,
the inhibitory function of IL1R2 is selectively attributed to this
long, membrane bound form [29].
Soluble IL1R2 levels, which reflect of the shorter IL1R2
message (affymetrix 211372), were reduced in AIED patients in
culture supernatants of PBMC stimulated with perilymph
measured by ELISA (figure 2C). This finding parallels our
microarray results for Affymetrix probe 211372 (not shown) and
our Q-RT-PCR expression of sIL1R2 in AIED and control
subjects (figure 2B). Interestingly, at least for the AIED cochlear
implant recipients, there did not appear to be increased sIL1R2 as
the mechanism for IL1R2 reduction compared to controls.
IL1R2 splicing correlates with clinical steroid
responsiveness
Only 60% of patients studied by the AIED study group were
steroid responsive [3]. To date, it is unknown why some AIED
patients respond while others do not, although presence of certain
antibodies have been correlated with steroid responsiveness
[14,15]. We hypothesized that robust expression of mIL1R2, in
response to corticosteroids may be indicative of a clinical response.
To test the hypothesis, we enrolled patients with acute deteriora-
tion of their hearing that met the same criteria that the AIED
study group used [3]. Blood for PBMC isolation was drawn
immediately prior to oral steroid therapy (60 mg of prednisone
daily for a minimum of 7 days with a variable taper thereafter). A
repeat audiogram was performed between 7–10 days post
initiation of treatment, and in a subset of patients, blood for
PBMC isolation was again drawn. Table 2 describes the eighteen
patients enrolled in this study. The average hearing recovery at all
frequencies tested is shown in Table 2. All responders returned to
their prior baseline hearing thresholds at the end of the
glucocorticoid therapy. Non-responders were defined as those
patients that showed less than 5 dB improvement at all frequencies
tested, or further decline in pure tone thresholds. In these studies,
we observed that pre-treatment expression of mIL1R2 mRNA by
PBMC in response to dexamethasone stimulation in vitro,
correlated with clinical responsiveness to oral steroid therapy.
Corticosteroid responders had absent pre-treatment, basal
mIL1R2 expression; however, they dramatically augmented
Figure 2. Expression of IL1R2 in cochlear implant recipients. 2A Diagram of IL1R2 mRNA depicting regions detected by microarray probes
and Q-RT-PCR primers. At position 1117, an alternate splice site has been described [25] that induces a stop codon. 2B Q-RT-PCR for 3 control
subjects and 5 AIED subjects comparing autologous perilymph stimulated to unstimulated PBMC for both the shorter soluble IL1R2 (sIL1R2) and the
longer membrane bound form of Il1R2 (mIL1R2). Results were dramatically different and statistically significant for mIL1R2 (as seen with an asterix (*)),
using a Mann Whitney test (p=0.03) (in stat). 2C ELISA for soluble IL-1R2 (sIL1R2). Supernatants from 16-hour PBMC cultures from 3 AIED patients and
2 controls were used to determine the level of soluble receptor. Stimulus conditions were no stimulus (white bar), pneumococcal stimulus (grey bar)
or autologous cochlear perilymph (black bar). Relative amounts were set at one for the unstimulated condition as this data set included 2 children
(one AIED, one control). sIL-1R2 levels are less in children however, a similar patterns of expression were observed. Standard deviations are shown.
doi:10.1371/journal.pone.0005293.g002
IL1R2 Expression and AIED
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PATIENT
PRIOR
TX? PMH SEROLOGY MRI
AFFECT
EAR
250
Hz
500
Hz
1000
Hz
2000
Hz
4000
Hz
AVG
Improve
56WM (NR1) YES NC NA NEG PRETX 35 45 60 105 120 21d B
POSTTX 40 45 60 105 120
42 WF
B (NR2) YES Hypo-thyroid ANA 1:320, Immune
complex +
NEG PRETX 50 75 90 95 95 21d B
POSTTX 55 75 95 95 90
61HF
B (NR3) YES NC NA NEG PRETX 65 60 40 35 45 23d B
POSTTX 70 60 50 35 45
57 WM
B (NR4) YES Brother W/Crohns ANA1:2560, P0 pos NEG PRETX 55 60 75 65 80 219 dB
POSTTX 60 70 75 70 75
45WM (NR 5) YES NC RF borderline + NEG PRETX 60 60 65 65 70 +2 dB (NS)
POSTTX 60 60 70 60 60
62 WF (NR6) YES NC Weak+68 kD Borderline
typeII collagen
NEG PRETX 10 10 10 10 40 29d B
POSTTX 15 15 10 10 55
60 WF (NR7) YES Pulm collag vasc
disease
P0 pos NEG PRETX 60 60 60 55 75 21d B
POSTTX 65 60 65 55 70
WM (NR8) YES Father w/Auto-
immune disease req.
steroids
Neg NEG PRETX 50 55 65 65 60 0 dB
POSTTX 50 55 65 60 65
46 WF (NR9) NO Multiple Sclerosis NA NEG PRETX 95 90 95 120 120 29d B
POSTTX 100 110 115 120 120
56 WF
B (R1) YES Daughter W/IDDM ANA 1:640, Phospholipid
IgG & IgM pos
NEG PRETX 55 60 60 40 40 +37 dB
POSTTX 15 20 15 5 15
54 WF
B (R2) YES Hashimotos
Thyroiditis
ANA 1:160, 68 kD pos NEG PRETX 105 115 100 100 100 +39 dB
POSTTX 40 60 70 80 75
39WM
B (R3) YES NC NA NEG PRETX 40 45 35 15 30 +15 dB
POSTTX 25 15 5 5 40
69 WF (R4) YES Crohn’s Disease NA NEG POSTTX 40 35 30 30 20 +6d B
POSTTX 20 35 25 30 15
59 WF (R5) YES Fibromyalgia NA NEG PRETX 105 105 105 100 95 +9d B
POSTTX 105 90 90 90 90
53 WM (R6) YES Psoriasis NA NEG PRETX 50 55 45 25 25 +17 dB
POSTTX 35 30 15 10 35
46 WM (R7) YES NC NA NEG PRETX 55 60 30 10 60 +11 dB
POSTTX 50 30 15 5 60
79 WF (R8) YES NC NA NEG PRETX 50 40 40 55 80 +11 dB
POSTTX 25 25 40 55 70
37 WF (R9) YES NC Neg NEG PRETX 20 30 45 60 75 +19 dB
POSTTX 10 15 20 35 55
‘‘Prior tx?’’: although all had prior rapid declines in hearing requiring prednisone therapy, none were treated in a 3 month period prior to enrollment. Several patients
had occasional vestibular symptoms, however, these symptoms did not coincide with periods of hearing fluctuation. Serology was performed at Immco Diagnostics.
NA=not available: serologic testing at Immco could not be performed as these tests were not covered b y the patient’s insurance carrier. Audiometric change shown
represents the change between the average of the post-treatment pure tone thresholds from the pre-treatment pure tone average threshold. NS=not significant:
average post-treatment hearing changes of less than 5 dB are not felt to represent significant changes. All declines in hearing are reported as 0 dB. NR=clinical non-
responder; R=clinical responder.
doi:10.1371/journal.pone.0005293.t002
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p,0.0001 (figure 3A), using a Mann Whitney test. Although the
mean and standard deviations are large in the groups largely due
to the steroid non-responsive patient that clustered with the steroid
responsive group, the median fold change of the non-responsive
group was 47 as compared to the median of the responsive group
was 2.37610
6. If we set a threshold for clinical steroid
responsiveness to be a greater than 500 fold induction of mIL1R2
in vitro, then the sensitivity of this test is 100% with a confidence
interval of 71.7 to 100%. The specificity would be 88.9% with a
confidence interval of 51.8–99.7%. The dramatic difference in the
pre-treatment fold change of the corticosteroid responders was
inversely proportional to basal mIL1R2 expression by unstimu-
lated PBMC (45 cycles, S.D. 0.0 in replicate samples), (denoted
‘‘unstim’’ in figure 3B), compared to corticosteroid non-responders
(28.48 cycles, S.D.63.34) (Figure 3B). Post-treatment basal
expression of mIL1R2 in steroid responders was detected at a
much lower cycle number by Q-RT-PCR than pre-treatment
(figure 3B). Pre-treatment basal mIL1R2 expression in glucocor-
ticoid-responders dramatically increased from no expression at 45
cycles to detectable expression at 30 cycles post-treatment,
compared with 30 cycles to 27 cycles post-treatment in non-
responders suggesting that the glucocorticoid responsiveness
correlated with induction of mIL1R2 RNA expression
(figure 3B). Furthermore, as seen with the cochlear implant
patients, despite absent mIL1R2 expression, sIL1R2 expression
was observed at reasonable levels (figure 3C). Interestingly, the
steroid refractory patients demonstrated high mIL1R2 expression
in absence of stimulation prior to treatment, with no major change
in expression in response to dexamethasone (figure 3B, denoted
‘‘dex stim’’). This expression pattern suggests some endogenous
stimulation of mIL1R2 expression.
It is paradoxical that AIED cochlear implant recipients
demonstrated absent basal expression of mIL1R2, yet steroid
refractory AIED patients exhibit high levels of mIL1R2 in absence
of in vitro stimulation. Steroid-refractory patients with high basal
Figure 3. Pre-treatment induced expression of mIL1R2 in response to dexamethasone correlates with post-treatment clinical
hearing restoration. 3A 18 patients with presumptive AIED and sudden declines in hearing were enrolled, blood drawn prior to treatment, and
treated with 60 mg prednisone/day67 days and then tapered. Pre-treatment PBMC were divided and incubated with either no stimulus or
dexamethasone (8 mg/ml is shown). IL1R2 mRNA was measured by Q-RT-PCR. Post-treatment audiograms were obtained between 7–14 days later.
Audiometric improvement (D) was measured as the average of 250, 500, 1,2,& 4 kHz. Responders (R) all returned to prior baseline hearing. Pre-
treatment levels of mIL-1R2 Q-RT-PCR (expressed as fold change over baseline) predicted steroid responsiveness in AIED (P,0.0001, Mann Whitney
test). 3B Pre and post treatment mIL1R2 levels in a subset of clinical responders and non-responders. Pre-treatment responders have no basal mIL1R2
expression in PBMC (unstim) at 45 cycles (in replicate samples), compared with non-responders that have substantially higher basal levels. Although
PBMC from both responders and non-responders demonstrate increased mIL1R2 RNA expression in response to in vitro dexamethasone stimulation
(dex stim), responders are exquisitely sensitive. The concentration of dexamethasone shown for the PBMC stimulation experiments was 20 ug/ml,
however, 4 ug/ml and 8 ug/ml produced identical results, suggesting maximal stimulation even at 4 ug/ml. 3C Despite clear differences in mIL1R2
expression patterns, sIL1R2 expression is differences between responders and non-responders are minimal suggesting alternate splicing in clinical
responders.
doi:10.1371/journal.pone.0005293.g003
IL1R2 Expression and AIED
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Alternatively, steroid-refractory patients have a different inflam-
matory microenvironment that overwhelms the effects of mIL1R2-
induced expression. The absent basal expression of mIL1R2 in
AIED cochlear implant recipients may reflect the absence of acute
inflammation at the time of implantation. Our results demonstrate
that low basal and induced expression of mIL1R2 in AIED during
periods of inflammation and rapid hearing decline correlated with
the clinical response to glucocorticoids.
Discussion
IL1R2 is known to be a molecular decoy that sequesters IL-1b,
and blocks the initiation of downstream signaling, thereby
preventing inflammation (as reviewed [30,31]. The IL1R2 protein
is expressed on B cells, monocytes/macrophages and neutrophils
[30], and may be expressed in response to many stimuli, including
oxygen radicals, IL-4, IL-13, and glucocorticoids [30], possibly
explaining the ability of steroids to ameliorate AIED. Release of
the soluble IL1R2 (sIL1R2) may also be induced by various
stimuli, although the major inhibitory function of IL1R2 has been
ascribed to the membrane bound form [29]. The induction of
IL1R2 by IL-4 [32] certainly suggests that the maintenance of a
TH2-like phenotype is important in controlling inner ear disease,
whereas expression of IFNc, that fosters a TH1-like response, has
been observed in AIED patients [22], and blocks the expression of
IL1R2 [33]. IL1R2 is an important mechanism that prevents IL-
1b-mediated inflammation at sites where inflammation is poorly
tolerated. In the brain, IL1R2 is preferentially expressed
compared to IL-1R1, the cognate IL-1b receptor [34]. Restoring
IL1R2 expression in IL1R2 deficient cells resulted in significant
cellular protection from IL-1b mediated damage [35]. Treatment
of mice with IL1R2 expressing cells reduced inflammation in
collagen-induced arthritis [36], demonstrating that IL1R2 may be
beneficial in diseases where IL-1b is dominant and endogenous
counteracting antagonists are absent.
In steroid responsive patients, sIL1R2 RNA was detected in
unstimulated PBMC, however, the long mIL1R2 transcript could
not be detected. In the presence of dexamethasone, the long
transcript could readily be detected. LPS stimulation of monocytes
results in reduced mRNA synthesis of IL1R2 [28]. Although
transcriptional induction of IL1R2 from dexamethasone stimula-
tion of monocytes has been studied extensively by Northern
analysis [37,38,39], alternate splicing has not been reported,
perhaps because these studies were performed in a limited number
of control subjects or small molecular weight shifts induced by
alternate splicing near the 39 end may not have been detected in
these studies. Dexamethasone has however, been reported to
induce differential splicing in other genes [40]. Furthermore,
alternate splicing of critical regulatory genes has been identified to
associate with risk of other autoimmune diseases, such as alternate
splicing of BANK1 in Systemic Lupus Erythematosus [41].
Investigation into whether genetic polymorphisms affect the
splicing of the IL1R2 message is underway in our laboratory.
Although it has been shown that no anatomic barrier exists
preventing leukocyte trafficking to the inner ear [2,18], the robust
expression of mIL1R2 in control cochlear implant subjects, and
AIED patients who responded to glucocorticoids suggests that the
inner ear likely is at least a partially functionally immunoprivileged
site. We hypothesize that AIED patients who experience a break in
tolerance and fail to express IL1R2 in response to antigenic
stimuli, have unopposed IL-1b expression that leads to hearing
loss. Unopposed expression of IL-1b has been shown to induce
sensorineural deafness in patients with Muckle-Wells syndrome, an
autoinflammatory disorder. In these patients, restoration of
hearing was observed following anakinra therapy, an IL-1 receptor
antagonist [42,43], with normalization of IL-1b serum levels [43].
We further hypothesized that the expression of IL1R2, in
response to various stimuli, likely represents an innate immune
response by macrophages. Macrophages are the predominant
producer of IL1R2 [37,39]. Macrophage ingress into the cochlea
has been demonstrated in traumatic injury: perhaps best
characterized during periods of acoustic-induced trauma [44].
Furthermore, during acoustic trauma, pro-inflammatory cyto-
kines, including IL-1b are expressed [45]. Similarly, IL-1b
expression was observed in response to LPS in an animal model
of AIED [20]. Reduction of mononuclear cell secretion of IL-1b
was observed following anakinra therapy and correlated with
hearing restoration in a patient with Muckle-Wells syndrome [43].
We hypothesize that as the AIED progresses, an increased
production of IFN-c blocks expression of IL1R2 in the cochlea.
Preliminary flow cytometry experiments demonstrate induction of
IL1R2 surface expression in response to dexamethasone occurs in
blood monocytes in these patients (not shown). We are also
examining the perilymph of these patients to ascertain whether it is
the cytokine microenvironment, or the presence of a unique
protein or autoantigen found in perilymph that is inducing
differential IL1R2 expression in perilymph from AIED and
controls.
To date, ability to identify glucocorticoid responsive AIED
patients prior to treatment has been limited to a correlation with
seropositivity for either HSP70 or CTCL2 [14,15]. Thus,
identifying mIL1R2 levels that predict steroid responsiveness early
on in disease may help better phenotype those with AIED, and
those who will benefit from this therapy thereby avoiding the
complications associated with this treatment in patients not
expected to respond.
The observations we describe suggest that mILR2 expression
may be an important mechanism involved in glucocorticoid
responsiveness in AIED; however, given that steroids control
inflammation by multiple mechanisms, it is probable that other
pathways contribute to the observed response. Clinical therapies
that alter IL-1b expression have not been used in AIED patients.
Methods
Patient Recruitment
Ethics Statement. These studies were approved by the
North Shore-LIJ Health System IRB. All patients signed written
consent for inclusion into these studies. In the case of the two
children, their parents provided written consent. Assent was not
obtained from the children due to their young age.
Cochlear Implant Subjects. All patients met current criteria
for cochlear implantation and had a bilateral profound SNHL. All
patients with AIED had periods of rapid hearing loss and were no
longer steroid responsive. All adult controls had stable SNHL for
over 30 years of clear, non-immunologic origin. A total of 9 patients
were recruited (7 adults 2 children) representing 4 controls and 5
with AIED, and their clinical demographics shown in table 1.
At the time of cochlear implant surgery; blood was drawn to
isolate PBMC. Perilymph fluid was harvested from the cochleost-
omy in a bloodless field. In order to control for a cochlear
perilymph specific response, we compared unstimulated PBMC, to
cochlear perilymph stimulated PBMC, and pneumococcal stimu-
lated PBMC, from both AIED and control patients. Three
microarrays were performed per study subject: 1) perilymph+au-
tologous PBMC, 2) pneumococcal antigen+autologous PBMC,
and 3) PBMC alone and administration of pneumococcal vaccine
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standard of care prior to cochlear implantation, served as a
positive control.
Prospectively Enrolled, Steroid Treated Subjects
Eighteen patients with AIED who had not undergone cochlear
implantation were studied in a separate IRB approved protocol
(Table2).Theyall hada clinicalhistorysuggestiveof AIED, andmet
criteriadefinedforAIEDtrials[3].Atthetimeofenrollment,theyall
demonstrated sudden declines in their hearing and weretreated with
60 mg of prednisone daily for 7 days with a variable taper thereafter.
The responders were defined as a 5 dB or greater average
improvement at 250, 500, 1000, 2000 and 4000 Hz. All patients
recruited must have had prior audiograms demonstrating their
baseline-hearing threshold. Furthermore, SNHL of greater than
30 dB at one or more frequencies in both ears with evidence of active
deterioration (elevated threshold) in at least one ear of 15 dB at one
frequency (excluding 250 Hz as a sole indicator), or 10 dB at 2+
frequencies developing in .3d a y sb u t,90 days [3,16]. If the
hearing lossevolved inlessthan3 days,priorsimilarhearing declines
musthaveoccurred or thepatientmusthave a systemicautoimmune
disorder AND the patient must meet the audiology criteria outlined
above. All patients with retrocochlear (vestibular schwannoma or
other internal auditory canal s) pathology), patients who received
prednisone or otherimmunosuppressive therapywithin3 months,or
patients with vestibular symptoms coinciding with periods of hearing
fluctuation [3] were all excluded from this study. All patients
received a minimum of 60 mg of prednisone daily for 7 days with a
variable taper thereafter.
Microarray Analysis. PBMC were isolated over a Ficoll-
hypaque gradient, divided into 5 ml cultures (2610
6 cells/ml) and
cultured in RPMI+10%FCS for 16 hours at 37uC with 5% CO2
with one of 3 stimuli (1) without antigenic stimulus (untx), (2)
100 ml pneumococcal vaccine [46] as a positive control (pneumo)
or (3) with 15 ml of autologous cochlear perilymph (c). RNA was
isolated using an affinity spin column (Qiagen) and 5 mg reverse
transcribed into double stranded cDNA (Invitrogen) incorporating
a T7 RNA polymerase promoter. The cDNA was phenol
extracted, ethanol precipitated and biotinlyated cRNA generated
by in vitro transcription (ENZO). cRNA was purified on a spin
column (Qiagen), quantitated, and 20 mg fragmented and
hybridized to the Affymetrix HG U133A 2.0 array (Affymetrix).
Data sets were normalized using RMA and an ANOVA analysis
was performed on grouped arrays by condition with a Benjamini
and Hochberg correction, and a threshold of 2.0 fold change
(Genesifter, VixXlabs). Array data in 1A can be viewed at www.
ncbi.nlm.nih.gov/geo/ using the user ‘‘Vambutas’’ with a
password ‘‘daniella’’ to view series ‘‘GSE4277’’ containing 18
arrays from the six patients with ‘‘1’’ next to their description in
table 1. The array data is MIAME compliant. Upon publication,
this data will be publicly released, with the password removed.
Q-RT-PCR. Quantitative Real Time RT-PCR (Q-RT-PCR)
was performed on PBMC from patients using TaqMan chemistry.
The relative abundance of IL1R2 mRNA for 2 membrane bound
(mIL1R2) and the soluble (sIL1R2) coding regions associated with
the 2 affymetrix probes sets 211372 (sIL1R2) and 205403
(mIL1R2) were compared to b-actin was determined using the
Eurogentec RTqPCR mastermix (Eurogentec, Belgium) and ABI
PRISM 7700 Sequence Detection System. Membrane bound
IL1R2, as reflected by affymetrix probe set 205403 was detected
by primers nt 1239–1258, 1295–1314, and taqman probe 1271–
1278, whereas the shorter soluble form (sIL1R2) reflected by the
affymetrix probe 211372 and primers nt 790–830–849, and
taqman probe 820–827. The alternative splice site described by
Liu changing GAA to TAA, introducing a stop codon, occurs at nt
1118 [25]. These primers were added at final concentration of
200 nM and 100 nM respectively to 50 ng of total RNA. The
conditions were 48uC for 309,9 5 u C for 109 and 45 cycles of 95uC
for 150 and 60uC for 19. Data was analyzed using Sequence
Detection System software version 1.9.1. Results were expressed as
Ct (Threshold cycle) values, which is inversely proportional to the
starting template copy number. Relative abundance of IL1R2 in
cochlear fluid stimulated cells was calculated compared to
untreated control samples using delta delta Ct method (User
Bulletin #2, ABI). In all prospectively enrolled, steroid treated
patients, the unstimulated condition is the average of 2
independent PBMC cultures (SD for responders was 0.0, and
SD for non-responders was 3.34 cycles).
ELISA Analysis. ELISA for soluble IL-1R2 (sIL-1-R2).
Supernatants from 16-hour PBMC cultures from 3 AIED
patients and 2 controls were used to determine the level of
soluble receptor (See table 1 for inclusion). ELISA was performed
according to manufacturers’ instructions (R&D Systems). Stimulus
conditions were either pneumococcal stimulus as used above or
autologous cochlear perilymph and compared to unstimulated
PBMC. A large number of duplicate samples were run to ensure
accuracy.
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